Eligard®: Advantages for Optimal Testosterone Control

European Urology, Supplements

Volumn 5, Issue 18, 2006, Pages 900-904

  Tombal, Bertrand ^a   Berges, Richard ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b PAN Klinik am Neumarkt   (Germany)

Author keywords

Hormone therapy; Intermittent; Leuprolide; LHRH agonists; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

ATRIGEL; BICALUTAMIDE; BUSERELIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; POLYMER; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; MEDLINE; ORCHIECTOMY; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; REVIEW; URINARY TRACT DISEASE;

EID: 33749259757     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.08.007     Document Type: Review

References (33)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Huggins C., Stevens R., and Hodges C.V. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
3. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
4. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 22 (1971) 703-721
5. Coy D., Vilchez-Martinez J., Coy E., Arimura A., and Schally A.V. A peptide inhibitor of luteinizing hormone-releasing hormone (LH-RH). J Clin Endocrinol Metab 37 (1973) 331-333
6. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5 (1982) 267-275
7. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 (1998) 1036-1042
8. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346 (1995) 265-269
9. Klotz L., Schellhammer P., and Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 93 (2004) 1177-1182
10. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
11. Cassileth B.R., Soloway M.S., Vogelzang N.J., et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1 (1992) 323-329
12. Vogelzang N.J., Chodak G.W., Soloway M.S., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46 (1995) 220-226
13. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 (2001) 3750-3757
14. Zlotta A., and Debruyne F.M.J. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 4 8 (2005) 37-41
15. ®?. Eur Urol Suppl 4 8 (2005) 30-36
16. Oefelein M.G., Feng A., Scolieri M.J., Ricchiutti D., and Resnick M.I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 (2000) 1021-1024
17. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone?. Eur Urol Suppl 4 5 (2005) 14-19
18. Popov I., Jelic S., Radosavljevic D., and Nikolic-Tomasevic Z. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer-speculations about possible role of the monoamine system. Neoplasma 44 (1997) 308-313
19. Oefelein M.G., and Resnick M.I. Effective testosterone suppression for patients with prostate cancer: is there a best castration?. Urology 62 (2003) 207-213
20. Sarosdy M.F., Schellhammer P.F., Soloway M.S., et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (1999) 801-806
21. Sharifi R., and Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 168 (2002) 1001-1004
22. Khan M.S., and O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3 M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 60 (1998) 33-40
23. Fontana D., Mari M., Martinelli A., et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 70 (2003) 316-320
24. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 60 (1998) 18-24
25. Perez-Marrero R., and Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 5 (2004) 447-457
26. Perez-Marreno R., Chu F.M., Gleason D., Loizides E., Wachs B., and Tyler R.C. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24 (2002) 1902-1914
27. Chu F.M., Jayson M., Dineen M.K., Perez R., Harkaway R., and Tyler R.C. A clinical study of 22.5 mg La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 168 (2002) 1199-1203
28. ®: pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl 4 5 (2005) 20-25
29. Berges R., and Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 22 (2006) 649-655
30. Sharifi R., Bruskewitz R.C., Gittleman M.C., Graham Jr. S.D., Hudson P.B., and Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 18 (1996) 647-657
31. Rizzo M., Mazzei T., Mini E., Bartoletti R., and Periti P. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res 18 (1990) 114-125
32. Fowler J.E., Gottesman J.E., Reid C.F., Andriole G.L., and Soloway M.S. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 164 (2000) 730-734
33. Wechsel H.W., Zerbib M., Pagano F., and Coptcoat M.J. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1 M and 3 M depot in patients with advanced prostatic cancer. Eur Urol 30 (1996) 7-14